Nemtabrutinib

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameNemtabrutinib
Drug Alias NameARQ-531MK-1026
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsRichter's SyndromeHepatic InsufficiencyHematologic Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesArqule Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer InstituteMerck Sharp & Dohme CorpArqule Inc +[6] 
Inactive CompaniesN/A
Active IndicationsRichter's SyndromeHepatic InsufficiencyHematologic Neoplasms +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG